Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

NCT07189793 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

106

Enrollment

OTHER

Sponsor class

Conditions

Urinary Bladder Neoplasms
Carcinoma, Transitional Cell
Carcinoma in Situ of Bladder
Non-Muscle-Invasive Bladder Cancer

Interventions

DRUG: Toripalimab
DRUG: Gemcitabine (GEM)
DRUG: Mitomycin C (MMC)

Sponsor

First Affiliated Hospital of Wenzhou Medical University